Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Minority Interest (2016 - 2019)

Spero Therapeutics' Minority Interest history spans 4 years, with the latest figure at $355000.0 for Q3 2019.

  • For Q3 2019, Minority Interest changed 0.0% year-over-year to $355000.0; the TTM value through Sep 2019 reached $355000.0, changed 0.0%, while the annual FY2018 figure was $355000.0, 0.0% changed from the prior year.
  • Minority Interest reached $355000.0 in Q3 2019 per SPRO's latest filing, roughly flat from $355000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $6.4 million in Q2 2017 to a low of -$3.8 million in Q4 2016.
  • Average Minority Interest over 4 years is $526636.4, with a median of $355000.0 recorded in 2017.
  • Peak YoY movement for Minority Interest: skyrocketed 109.32% in 2017, then tumbled 94.45% in 2018.
  • A 4-year view of Minority Interest shows it stood at -$3.8 million in 2016, then soared by 109.32% to $355000.0 in 2017, then changed by 0.0% to $355000.0 in 2018, then changed by 0.0% to $355000.0 in 2019.
  • Per Business Quant, the three most recent readings for SPRO's Minority Interest are $355000.0 (Q3 2019), $355000.0 (Q2 2019), and $355000.0 (Q1 2019).